10x Genomics (NASDAQ:TXG) Reaches New 1-Year High Following Strong Earnings

10x Genomics (NASDAQ:TXG)’s share price reached a new 52-week high during mid-day trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $50.47 and last traded at $50.0750, with a volume of 2508566 shares changing hands. The stock had previously closed at $45.60.

The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.10. The company had revenue of $151.04 million for the quarter, compared to the consensus estimate of $146.67 million. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The firm’s revenue was down 12.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.28 EPS.

Key Headlines Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported second-quarter revenue of $151.0 million, above the $146.7 million analyst consensus, while its adjusted loss of $0.14 per share was narrower than the expected $0.24 loss. 10x Genomics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 revenue outlook to $610 million-$630 million, with the midpoint modestly above the roughly $613.8 million consensus estimate. The improved outlook was a key catalyst for the stock’s positive reaction. 10x Genomics Raises 2026 Revenue Outlook
• Positive Sentiment: Management indicated that Atera shipments remain at approximately 40 units, supporting the company’s commercial instrument rollout and potentially future recurring consumables revenue. 10x Genomics Q2 2026 Earnings Call Transcript
• Neutral Sentiment: The quarterly earnings and guidance updates were broadly ahead of expectations, but the revenue outlook represents only a modest improvement relative to analyst forecasts. 10x Genomics Q2 2026 Outlook
• Negative Sentiment: 12.7% year over year, and the company reported a loss compared with earnings of $0.28 per share in the prior-year quarter. 10x Genomics also continues to have negative margins and return on equity. 10x Genomics Reports Q2 Loss

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. TD Cowen reissued a “hold” rating on shares of 10x Genomics in a research note on Wednesday, July 15th. Morgan Stanley set a $40.00 target price on 10x Genomics and gave the stock an “equal weight” rating in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of 10x Genomics in a research note on Wednesday, June 24th. JPMorgan Chase & Co. upped their price objective on shares of 10x Genomics from $17.00 to $20.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Finally, Leerink Partners increased their target price on shares of 10x Genomics from $23.00 to $40.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and an average target price of $34.42.

Insider Buying and Selling

In related news, CFO Adam Taich sold 15,098 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $368,995.12. Following the completion of the sale, the chief financial officer owned 379,898 shares of the company’s stock, valued at $9,284,707.12. This represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Serge Saxonov sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $34.44, for a total transaction of $1,033,200.00. Following the completion of the sale, the chief executive officer owned 1,108,380 shares of the company’s stock, valued at approximately $38,172,607.20. This trade represents a 2.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 91,309 shares of company stock worth $2,581,357 in the last three months. 8.84% of the stock is owned by company insiders.

Institutional Trading of 10x Genomics

A number of institutional investors have recently made changes to their positions in TXG. Geneos Wealth Management Inc. purchased a new stake in 10x Genomics in the fourth quarter valued at about $38,000. Larson Financial Group LLC increased its holdings in shares of 10x Genomics by 164.4% during the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after acquiring an additional 1,470 shares in the last quarter. Fifth Third Bancorp acquired a new position in shares of 10x Genomics during the first quarter valued at about $50,000. Elevation Wealth Partners LLC raised its position in shares of 10x Genomics by 332.3% in the 2nd quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock valued at $57,000 after purchasing an additional 1,143 shares during the last quarter. Finally, Van ECK Associates Corp raised its position in shares of 10x Genomics by 85.9% in the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock valued at $60,000 after purchasing an additional 1,695 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Stock Performance

The business’s 50 day moving average is $38.81 and its 200 day moving average is $27.45. The company has a market capitalization of $6.37 billion, a price-to-earnings ratio of -296.56 and a beta of 2.03.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.